Welcome • 53rd International Conference on Drug Development
ICD2 • February 24 & 25, 2014 • Austin
The University of Texas at Austin College of Pharmacy Division of Pharmaceutics and the distinguished members of the Planning Committee welcomes you to the 53rd annual International Conference on Drug Development (ICD2), February 24 & 25, 2014 in Austin, Texas, USA.
ICD2 continues its tradition of offering an informal forum for the exchange of ideas concerning the drug discovery and drug development process.
The conference brings together national and international scientists from academia, the pharmaceutical industry, the biotechnology industry and regulatory agencies for the opportunity to learn of and discuss new initiatives for finding a better way to develop new drugs as well as to improve the quality of existing drug products.
VIEW LETTER OF INVITATION
2014 Conference Theme
Transformation of Drug Development – Challenges and Opportunities
Advancing Innovative Solutions to Meet Patient’s Medical Needs of Serious Conditions and Rare Diseases
To offer the most informative and up to date conference in the science and regulation of global drug development
|Round Table Discussion on a on finding solutions to quality and safety challenges of Breakthrough Therapies as well as building data to minimize risk and systems to maximize lifecycle quality - presentations and discussion lead by Rick Friedman, MS • FDA; Roger Nosal, PhD • Pfizer; Mwango Kashoki, MD • Novartis; Debra Rasmussen, MBA, RAC •Janssen; and Moheb Nasr, PhD • GlaxoSmithKline|
|Janet Woodcock, MD, Director of CDER, FDA will present an update on the Expediting Drug Development process including discussion on scientific, clinical, and regulatory consideration of breakthrough therapies and accelerated approvals.
|Round Table Discussion on transforming and expediting drug development - presentations and discussion lead by Janet Woodcock, MD • FDA; Ray Sacchetti • Bristol-Myers Squibb; J. Russell Teagarden, DMH, RPh • NORD; Ethan Basch, MD • UNC; Isaam Zineh, PharmD • FDA|
|• Janet Woodcock, MD • Director of CDER FDA
• Mwango Kashoki, MD • Medical Officer, Office of New Drugs, FDA
• Mehul Mehta, Ph.D • Director, Division of Clinical Pharmacology, FDA
• Isaam Zineh, PharmD • Director, Office of Translational Sciences, FDA
|Round Table Discussion on a vision for expedited drug development in the XXI Century - presentations and discussion lead by Donald Berry, PhD • MD Anderson; Paula Rinaldi • Novartis; Carlo Russo, MD • GlaxoSmighKline; Lisa Bell, PhD • BioMarin; Sandy Allerheiligen, PhD • Merck; Janet Woodcock, MD • FDA|
Why Attend ICDD
ICD2 is known for bringing together national and international scientists from academia, the pharmaceutical industry, the biotechnology industry and regulatory agencies for the opportunity to learn of and discuss new initiatives for finding a better way to develop new drugs and improve the quality of existing drug products.
"The tremendous strengths of the ICD2 is the fact that you have top people from the FDA, top people from industry, top people from other organizations, the legal groups, academic institutions all getting together and really trying to hash out some of the major challenges that the industry and the environment is dealing with and find ways to move forward."
Kenneth I. Kaitin, Ph.D.
Professor and Director, Tufts Center for the Study of Drug Development, Tufts University
The conference includes an FDA panel discussion that provides conference participants the opportunity to direct questions and comments to the panel of FDA members for thought and discussion.
"I have found it one of the most impactful conferences that I attend."
Janet Woodcock, M.D.
Director of the Center for Drug Evaluation and Research, US Food and Drug Administration
Ample time is provided for questions and discussion, to expand upon particular points of interest throughout the conference.
"The ICD2 is an incredibly intimate setting which allows dialogue on cutting edge topics with not only senior scientists and policy makers at the FDA, but academicians and other senior scientists and executives from industry, the opportunity to exchange that dialogue and discuss those topics in not only a small, intimate conference setting, but also over three meals a day, is really a unique opportunity. It’s not a typical conference."
Joanne Palmisano, M.D., FACP
Vice President, Drug Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.
ICD2 was designed to fit the demands of today's top drug development professionals. The conference boasts 20+ presenters and panelists in one and a half days. Presentations and discussion will run through the evening hours on both days, resulting in a format that allows for travel time on Monday morning and early departure on Wednesday. Rates include program, meals, breaks, and accommodations resulting in one of the best values in drug development meetings at this level.
"If there’s any person who’s involved in any way with or wants to know about regulatory issues that are facing the industry, they ought to be at this meeting."
Gerald J. Yakatan, Ph.D.
Founder & Chairman, IriSys, Inc.
This conference is intended for leaders in Academia, the Pharmaceutical and Biotechnology Industry (PhRMA, BIO, GPhA), contract research organizations, API manufacturers, and domestic and international regulatory agencies in positions to affect the science and regulation of drug discovery and development, who wish to stay abreast on the national and international initiatives affecting the development of safe and effective pharmaceutical drug products.
|The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
|Comments to: UTPharmacyCE@austin.utexas.edu
Download free PDF Reader | Download free MS Reader
©2012 College of Pharmacy, The University of Texas at Austin